BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kosti P, Maher J, Arnold JN. Perspectives on Chimeric Antigen Receptor T-Cell Immunotherapy for Solid Tumors. Front Immunol 2018;9:1104. [PMID: 29872437 DOI: 10.3389/fimmu.2018.01104] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 13.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen Y, Yu Z, Tan X, Jiang H, Xu Z, Fang Y, Han D, Hong W, Wei W, Tu J. CAR-macrophage: A new immunotherapy candidate against solid tumors. Biomed Pharmacother 2021;139:111605. [PMID: 33901872 DOI: 10.1016/j.biopha.2021.111605] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Ponterio E, De Maria R, Haas TL. Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture. Front Immunol 2020;11:565631. [PMID: 33101285 DOI: 10.3389/fimmu.2020.565631] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
3 . Editor's Pick: Tumour-Associated Hypoxia: Can We Give Chimeric Antigen Receptor T Cells More Breathing Space? EMJ. [DOI: 10.33590/emj/20-00076] [Reference Citation Analysis]
4 Yu S, Wang Y, He P, Shao B, Liu F, Xiang Z, Yang T, Zeng Y, He T, Ma J, Wang X, Liu L. Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment. Front Oncol 2022;12:809304. [DOI: 10.3389/fonc.2022.809304] [Reference Citation Analysis]
5 Jo Y, Ali LA, Shim JA, Lee BH, Hong C. Innovative CAR-T Cell Therapy for Solid Tumor; Current Duel between CAR-T Spear and Tumor Shield. Cancers (Basel) 2020;12:E2087. [PMID: 32731404 DOI: 10.3390/cancers12082087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jenkins J, Park J, Petersen K, Shajihan K, Kruthiventi S, Betenbaugh M. Adoptive T cell therapy: engineering and biomanufacturing chimeric antigen receptor-T cell. Current Opinion in Chemical Engineering 2018;22:26-33. [DOI: 10.1016/j.coche.2018.08.006] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
7 Zhao R, Cui Y, Li S, Qin L, Li P. Current status and hurdles for CAR-T cell immune therapy. Blood Science 2019;1:148-55. [DOI: 10.1097/bs9.0000000000000025] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 Simon B, Uslu U. CAR-T cell therapy in melanoma: A future success story? Exp Dermatol 2018;27:1315-21. [PMID: 30288790 DOI: 10.1111/exd.13792] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
9 Liu D, Badeti S, Dotti G, Jiang JG, Wang H, Dermody J, Soteropoulos P, Streck D, Birge RB, Liu C. The Role of Immunological Synapse in Predicting the Efficacy of Chimeric Antigen Receptor (CAR) Immunotherapy. Cell Commun Signal 2020;18:134. [PMID: 32843053 DOI: 10.1186/s12964-020-00617-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
10 Reppel L, Tsahouridis O, Akulian J, Davis IJ, Lee H, Fucà G, Weiss J, Dotti G, Pecot CV, Savoldo B. Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer. J Immunother Cancer 2022;10:e003897. [PMID: 35022195 DOI: 10.1136/jitc-2021-003897] [Reference Citation Analysis]
11 Bansal R, Reshef R. Revving the CAR - Combination strategies to enhance CAR T cell effectiveness. Blood Rev 2021;45:100695. [PMID: 32402724 DOI: 10.1016/j.blre.2020.100695] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
12 Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W, Wang H. TGF-β inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors. JCI Insight 2020;5:133977. [PMID: 31999649 DOI: 10.1172/jci.insight.133977] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 27.0] [Reference Citation Analysis]
13 Parriott G, Deal K, Crean S, Richardson E, Nylen E, Barber A. T-cells expressing a chimeric-PD1-Dap10-CD3zeta receptor reduce tumour burden in multiple murine syngeneic models of solid cancer. Immunology 2020;160:280-94. [PMID: 32144940 DOI: 10.1111/imm.13187] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
14 Grote S, Ureña-Bailén G, Chan KC, Baden C, Mezger M, Handgretinger R, Schleicher S. In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. Cells 2021;10:1020. [PMID: 33925968 DOI: 10.3390/cells10051020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zeng Y, Liu C, Gong Y, Bai Z, Hou S, He J, Bian Z, Li Z, Ni Y, Yan J, Huang T, Shi H, Ma C, Chen X, Wang J, Bian L, Lan Y, Liu B, Hu H. Single-Cell RNA Sequencing Resolves Spatiotemporal Development of Pre-thymic Lymphoid Progenitors and Thymus Organogenesis in Human Embryos. Immunity 2019;51:930-948.e6. [PMID: 31604687 DOI: 10.1016/j.immuni.2019.09.008] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 11.7] [Reference Citation Analysis]
16 Uslu U. Driving CAR T cells towards dermatologic oncology. J Dtsch Dermatol Ges 2021;19:359-62. [PMID: 33591642 DOI: 10.1111/ddg.14402] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Porcellini S, Asperti C, Corna S, Cicoria E, Valtolina V, Stornaiuolo A, Valentinis B, Bordignon C, Traversari C. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front Immunol 2020;11:99. [PMID: 32117253 DOI: 10.3389/fimmu.2020.00099] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
18 Chung H, Jung H, Noh JY. Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy. Int J Mol Sci 2021;22:12126. [PMID: 34830003 DOI: 10.3390/ijms222212126] [Reference Citation Analysis]
19 Liang J, Zhang H, Huang Y, Fan L, Li F, Li M, Yan Y, Zhang J, Li Z, Yang X. A CLDN18.2-Targeting Bispecific T Cell Co-Stimulatory Activator for Cancer Immunotherapy. Cancer Manag Res 2021;13:6977-87. [PMID: 34522140 DOI: 10.2147/CMAR.S330637] [Reference Citation Analysis]
20 Bajor M, Graczyk-jarzynka A, Marhelava K, Burdzinska A, Muchowicz A, Goral A, Zhylko A, Soroczynska K, Retecki K, Krawczyk M, Klopotowska M, Pilch Z, Paczek L, Malmberg K, Wälchli S, Winiarska M, Zagozdzon R. PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells. J Immunother Cancer 2022;10:e002500. [DOI: 10.1136/jitc-2021-002500] [Reference Citation Analysis]
21 Kučan Brlić P, Lenac Roviš T, Cinamon G, Tsukerman P, Mandelboim O, Jonjić S. Targeting PVR (CD155) and its receptors in anti-tumor therapy. Cell Mol Immunol 2019;16:40-52. [PMID: 30275538 DOI: 10.1038/s41423-018-0168-y] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 12.3] [Reference Citation Analysis]
22 Gilabert-Oriol R, Ryan GM, Leung AWY, Firmino NS, Bennewith KL, Bally MB. Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. Int J Mol Sci 2018;19:E2922. [PMID: 30261606 DOI: 10.3390/ijms19102922] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
23 Lanitis E, Kosti P, Ronet C, Cribioli E, Rota G, Spill A, Reichenbach P, Zoete V, Dangaj Laniti D, Coukos G, Irving M. VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J Immunother Cancer 2021;9:e002151. [PMID: 34389616 DOI: 10.1136/jitc-2020-002151] [Reference Citation Analysis]
24 Zhang GZ, Li TF, Han SY. Mesothelin-targeted CAR-T cells for adoptive cell therapy of solid tumors. Arch Med Sci 2021;17:1213-20. [PMID: 34522250 DOI: 10.5114/aoms.2019.84888] [Reference Citation Analysis]
25 Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, Taher MYM, Davies DM, Muliaditan T, Larcombe-Young D, Woodman N, Gillett CE, Thavaraj S, Maher J, Arnold JN. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med 2021;2:100227. [PMID: 33948568 DOI: 10.1016/j.xcrm.2021.100227] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
26 Schmidts A, Maus MV. Making CAR T Cells a Solid Option for Solid Tumors. Front Immunol 2018;9:2593. [PMID: 30467505 DOI: 10.3389/fimmu.2018.02593] [Cited by in Crossref: 67] [Cited by in F6Publishing: 64] [Article Influence: 16.8] [Reference Citation Analysis]
27 Nardo M, Motta TC, Colli LM, Avanzi MP. Associação Brasileira de Hematologia, Hematologia, Hemoterapia e Terapia Celular Consensus on genetically modified cells. Review article: Cell therapy in solid tumors. Hematol Transfus Cell Ther 2021;43 Suppl 2:S78-83. [PMID: 34794801 DOI: 10.1016/j.htct.2021.09.011] [Reference Citation Analysis]
28 Wen Q, Han T, Wang Z, Jiang S. Role and mechanism of programmed death-ligand 1 in hypoxia-induced liver cancer immune escape. Oncol Lett. 2020;19:2595-2601. [PMID: 32218809 DOI: 10.3892/ol.2020.11369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
29 Simon B, Uslu U. Fasten the seat belt: Increasing safety of CAR T-cell therapy. Exp Dermatol 2020;29:1039-45. [PMID: 32627228 DOI: 10.1111/exd.14131] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
30 Wei J, Guo Y, Wang Y, Wu Z, Bo J, Zhang B, Zhu J, Han W. Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol 2021;18:792-804. [PMID: 32999455 DOI: 10.1038/s41423-020-00555-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
31 Kurebayashi Y, Choyke PL, Sato N. Imaging of cell-based therapy using 89Zr-oxine ex vivo cell labeling for positron emission tomography. Nanotheranostics 2021;5:27-35. [PMID: 33391973 DOI: 10.7150/ntno.51391] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
32 Mochel JP, Ekker SC, Johannes CM, Jergens AE, Allenspach K, Bourgois-Mochel A, Knouse M, Benzekry S, Wierson W, LeBlanc AK, Kenderian SS. CAR T Cell Immunotherapy in Human and Veterinary Oncology: Changing the Odds Against Hematological Malignancies. AAPS J 2019;21:50. [PMID: 30963322 DOI: 10.1208/s12248-019-0322-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
33 Lu D, Wang Y, Zhang T, Wang F, Li K, Zhou S, Zhu H, Yang Z, Liu Z. Metabolic radiolabeling and in vivo PET imaging of cytotoxic T lymphocytes to guide combination adoptive cell transfer cancer therapy. J Nanobiotechnology 2021;19:175. [PMID: 34112200 DOI: 10.1186/s12951-021-00924-2] [Reference Citation Analysis]
34 Li N, Tang N, Cheng C, Hu T, Wei X, Han W, Wang H. Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway. Oncoimmunology 2020;9:1824643. [PMID: 33457103 DOI: 10.1080/2162402X.2020.1824643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
35 Wang S, Wang X, Zhou X, Lyerly HK, Morse MA, Ren J. DC-CIK as a widely applicable cancer immunotherapy. Expert Opin Biol Ther. 2020;20:601-607. [PMID: 32033522 DOI: 10.1080/14712598.2020.1728250] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
36 Harjunpää H, Llort Asens M, Guenther C, Fagerholm SC. Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment. Front Immunol 2019;10:1078. [PMID: 31231358 DOI: 10.3389/fimmu.2019.01078] [Cited by in Crossref: 112] [Cited by in F6Publishing: 112] [Article Influence: 37.3] [Reference Citation Analysis]
37 Osipov A, Murphy A, Zheng L. From immune checkpoints to vaccines: The past, present and future of cancer immunotherapy. Adv Cancer Res 2019;143:63-144. [PMID: 31202363 DOI: 10.1016/bs.acr.2019.03.002] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
38 Kristi N, Gafur A, Kong L, Ma X, Ye Z, Wang G. Atomic Force Microscopy in Mechanoimmunology Analysis: A New Perspective for Cancer Immunotherapy. Biotechnol J 2020;15:e1900559. [PMID: 32240578 DOI: 10.1002/biot.201900559] [Reference Citation Analysis]
39 Date V, Nair S. Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors. Expert Opin Biol Ther 2021;21:145-60. [PMID: 32882159 DOI: 10.1080/14712598.2020.1819978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
40 Larcombe-Young D, Papa S, Maher J. PanErbB-targeted CAR T-cell immunotherapy of head and neck cancer. Expert Opin Biol Ther 2020;20:965-70. [PMID: 32567382 DOI: 10.1080/14712598.2020.1786531] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
41 Lee IK, Song H, Kim H, Kim IS, Tran NL, Kim SH, Oh SJ, Lee JM. RORα Regulates Cholesterol Metabolism of CD8+ T Cells for Anticancer Immunity. Cancers (Basel) 2020;12:E1733. [PMID: 32610705 DOI: 10.3390/cancers12071733] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
42 Thakur A, Scholler J, Kubicka E, Bliemeister ET, Schalk DL, June CH, Lum LG. Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells. Front Immunol 2021;12:690437. [PMID: 34290709 DOI: 10.3389/fimmu.2021.690437] [Reference Citation Analysis]
43 Del Vecchio C, Calistri A, Parolin C, Mucignat-Caretta C. Lentiviral Vectors as Tools for the Study and Treatment of Glioblastoma. Cancers (Basel) 2019;11:E417. [PMID: 30909628 DOI: 10.3390/cancers11030417] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
44 Uslu U. CAR-T-Zellen auf dem Weg zur praktischen Anwendung in der dermatologischen Onkologie. J Dtsch Dermatol Ges 2021;19:359-63. [PMID: 33709602 DOI: 10.1111/ddg.14402_g] [Reference Citation Analysis]
45 Sun Q, Zhang X, Wang L, Gao X, Xiong Y, Liu L, Wei F, Yang L, Ren X. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human. Cell Death Dis 2019;10:475. [PMID: 31209257 DOI: 10.1038/s41419-019-1717-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
46 Chen L, Qin D, Guo X, Wang Q, Li J. Putting Proteomics Into Immunotherapy for Glioblastoma. Front Immunol 2021;12:593255. [PMID: 33708196 DOI: 10.3389/fimmu.2021.593255] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Ghoneum A, Abdulfattah AY, Warren BO, Shu J, Said N. Redox Homeostasis and Metabolism in Cancer: A Complex Mechanism and Potential Targeted Therapeutics. Int J Mol Sci 2020;21:E3100. [PMID: 32354000 DOI: 10.3390/ijms21093100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 6.5] [Reference Citation Analysis]
48 Zhao Y, Liu Z, Li L, Wu J, Zhang H, Zhang H, Lei T, Xu B. Oncolytic Adenovirus: Prospects for Cancer Immunotherapy. Front Microbiol 2021;12:707290. [PMID: 34367111 DOI: 10.3389/fmicb.2021.707290] [Reference Citation Analysis]
49 Ma Q, Long W, Xing C, Chu J, Luo M, Wang HY, Liu Q, Wang RF. Cancer Stem Cells and Immunosuppressive Microenvironment in Glioma. Front Immunol 2018;9:2924. [PMID: 30619286 DOI: 10.3389/fimmu.2018.02924] [Cited by in Crossref: 57] [Cited by in F6Publishing: 57] [Article Influence: 14.3] [Reference Citation Analysis]
50 Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors. Invest New Drugs 2021;39:34-51. [PMID: 32772342 DOI: 10.1007/s10637-020-00978-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
51 Zhou J, Chen J, Huang Y, Gao X, Zhou C, Meng X, Sun J. Signaling Dynamics of TSHR-Specific CAR-T Cells Revealed by FRET-Based Biosensors. Front Cell Dev Biol 2022;10:845319. [DOI: 10.3389/fcell.2022.845319] [Reference Citation Analysis]
52 Volpe A, Lang C, Lim L, Man F, Kurtys E, Ashmore-Harris C, Johnson P, Skourti E, de Rosales RTM, Fruhwirth GO. Spatiotemporal PET Imaging Reveals Differences in CAR-T Tumor Retention in Triple-Negative Breast Cancer Models. Mol Ther 2020;28:2271-85. [PMID: 32645298 DOI: 10.1016/j.ymthe.2020.06.028] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
53 Schurich A, Magalhaes I, Mattsson J. Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors. Immunotherapy 2019;11:335-45. [PMID: 30678555 DOI: 10.2217/imt-2018-0141] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 12.0] [Reference Citation Analysis]
54 Zhao L, Cao YJ. Engineered T Cell Therapy for Cancer in the Clinic. Front Immunol 2019;10:2250. [PMID: 31681259 DOI: 10.3389/fimmu.2019.02250] [Cited by in Crossref: 81] [Cited by in F6Publishing: 71] [Article Influence: 27.0] [Reference Citation Analysis]
55 Guerrouahen B, Elnaggar M, Al-Mohannadi A, Kizhakayil D, Bonini C, Benjamin R, Brentjens R, Buchholz CJ, Casorati G, Ferrone S, Locke FL, Martin F, Schambach A, Turtle C, Veys P, van der Vliet HJ, Maccalli C; EICCI Faculty Group. Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar. Front Immunol 2020;11:589381. [PMID: 33584653 DOI: 10.3389/fimmu.2020.589381] [Reference Citation Analysis]
56 Harrop R, O'Neill E, Stern PL. Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen. Ther Adv Vaccines Immunother 2019;7:2515135518821623. [PMID: 30719508 DOI: 10.1177/2515135518821623] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]